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Despite an overall decrease in human expo-
sure to lead in recent years (1-4), the
potential for high intake of this contami-
nant still exists in millions ofhomes and in
many occupational settings. Moreover,
there is growing evidence that levels oflead
intake considered inconsequential just a
few years ago can result in a variety ofsub-
tle, adverse health effects in the absence of
overt intoxication (4-7). Lead poses a par-
ticularly great threat to young children,
who have elevated contact with lead in
dust, soil, and paint, elevated gastrointesti-
nal absorption oflead, elevated turnover of
bone lead into blood, and incompletely
developed organs and defense mechanisms.
The growing awareness of the health
threat posed by lead has stimulated in-
creased efforts to develop a detailed charac-
terization ofthe biological behavior oflead
in humans of all ages. Several biokinetic
models for lead have now been published
(8-20). Most of these were derived as
curve fits to limited data from controlled
metabolic studies on adult human volun-
teers or laboratory animals at different
stages oflife. In some cases an attempt has
been made to improve upon such expo-
sure-specific characterizations of lead
metabolism by synthesizing data from a
variety of exposure conditions (18,19) or
introducing greater physiological realism
into the modelingprocess (15,20).
In an effort motivated largely by the
Chernobyl nuclear accident, the Inter-
national Commission on Radiological
Protection (ICRP) is assembling a set of
age-specific biokinetic models for environ-
mentally important radioelements (21,22).
To this point, models for bone-seeking ele-
ments have been developed within one of
two generic model structures. One ofthese
applies to the "bone-surface-seeking" ele-
ments, including plutonium, americium,
neptunium, and thorium (23). The other
applies to the "bone-volume-seeking" or
"calciumlike" elements, including stron-
tium, barium, radium, and lead. Each of
these model frameworks represents awork-
able compromise between biological real-
ism and practical considerations regarding
the amount and quality of information
available to determine parameter values.
The generic structure for the calciumlike
elements provides a useful setting in which
to synthesize experimental, occupational,
and environmental data on lead and to
exploit common physiological properties of
lead and the alkaline earth elements.
The purposes of this paper are to
explain the conceptual basis of the lead
model as developed for the ICRP and
expand that model to include features that
are useful for consideration of lead as a
chemical toxin but that are unimportant
for consideration of lead as a radiological
toxin. In contrast to the version of this
model developed for the ICRP, the ex-
panded version includes a relatively de-
tailed description ofcirculating lead, a con-
centration-dependent transfer rate into red
blood cells (provided the lead concentra-
tion in red blood cells exceeds a specified
threshold level), and consideration of the
brain as a separate compartment.
BriefOverviewofthe Model
The model describes the time-dependent
distribution and excretion oflead that has
been injected or absorbed into blood. This
systemic model may be used in conjunc-
tion with any model describing the translo-
cation of lead from the respiratory or gas-
trointestinal tract into blood. The respira-
tory and gastrointestinal models used in
the present paper to evaluate human expo-
sure data or to compare model predictions
with observations ofthe fate ofinhaled or
ingested lead are described in the appendix.
A schematic diagram of the compart-
ments used in the systemic model and
directions of movement of lead among
these compartments is given in Figure 1. A
more detailed schematic diagram ofthe cir-
culation, i.e., the model for lead in blood
andrapidlyexchanging extravascular fluids,
is shown in Figure 2.
Transport of lead between compart-
ments is assumed to follow first-order
kinetics provided the concentration in red
blood cells (RBCs) stays below a nonlinear
threshold concentration. When the con-
centration in RBCs exceeds that threshold,
the transfer rate from diffusible plasma to
RBCs is assumed to decrease as the con-
centration in RBCs increases. At the same
time, the deposition fractions in other
compartments are increaseddue to decreased
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Figure 1. Compartments and paths of movement in the biokinetic model for lead. The systemic model may
be used in conjunction with any model of absorption from the lungs or gastrointestinal tract The 'plasma-
EVF" box, including RBCs, represents the model ofthe circulation, which isshown in more detail in Figure 2.
competition from the RBCs, but first-
order transport between all other compart-
ments is assumed to be maintained at all
levels of exposure. A nonlinear threshold
concentration of 60 pg/dl RBC (corre-
sponding to a blood lead concentration of
about 25 pg/dl) is assigned.
Transfer rates between compartments
are given in Table 1 for the six age groups
considered in Publication 56 of the Inter-
national Commission on Radiological
Protection (21,22). Transfer rates for ages
intermediate to those addressed in Table 1
are obtained by interpolating linearly with
age between the listed rates. For example, a
transfer rate for age 4 years is calculated as
0.25 times the rate given for age 1 year
plus 0.75 times the rate given for age 5
years. Changes with age in the biokinetics
oflead during adulthood are not addressed
here, but variation with adult age in the
rate of bone turnover, in particular, can
easily be included in the model if desired
(23,24).
Several software packages are available
for solving the type of compartmental
model described here. A particularly ele-
mentary and efficient method of solution
developed at this laboratory is described in
a recent paper (25).
Definitions
The "removal half-time" from a compart-
ment refers here to the biological half-time
that onewould observe, theoretically, ifout-
flow from that compartment continued
while feeds from all other compartments
were stopped. The removal half-time is
shorter than the apparent half-time in the
presence ofrecycling. For example, with the
model structure used here, the estimated
removal half-time from RBCs to diffusible
plasma is 5 days, but the half-time in RBCs
that is apparent to the outside observer is a
few weeks because the RBCs continually
take up lead that has been released to plas-
mafrom bone, soft tissues, and RBCs.
The term "transfer rate" as used here
indicates fractional transfer per unit time
from one compartment to another. (Note
that the transfer rates in this model are not
actually rate "constants" because in many
cases they change with age and hence time.)
The "total transfer rate" from a compart-
ment refers to the sum oftransfer rates from
that compartment to all destinations. For
example, the total transfer rate from dif-
fusible plasma to all other compartments is
estimated as 2000/day, which corresponds
to a removal half-time from diffusible plas-
maofln(2)/(2000/day) = 0.00035 day = 0.5
min. Parameter values are expressed as
Figure 2. Model ofthe circulation. Diffusible plas-
ma is viewed asthe central feeding compartment
and extravascular fluids (EVF) are treated as a
satellite compartment. Lead that moves between
plasma and retention sites in tissues istreated, in
effect, as if it passed instantaneouslythrough the
EVF.
transfer rates (per day) between compart-
ments because software packages for imple-
menting compartmental models usually
require transfer rates as input. Most of the
derived transfer rates are secondary values,
however, calculated from selected removal
half-times anddeposition fractions.
The term "deposition fraction" as used
here refers to instantaneous fractional out-
flow from the diffusible plasma compart-
ment. For example, a deposition fraction of
0.24 is assigned to RBCs. This means that
24% of the lead atoms leaving plasma in a
short time (seconds) are assigned to the
RBCs compartment. Since the total transfer
rate from diffusible plasma to all destina-
tions combined is estimated as 2000/day,
the transfer rate from diffusible plasma to
RBCs is 0.24 x (2000/day) = 480/day. The
use ofdeposition fractions provides one way
ofintroducingconsideration ofmaterial bal-
ance and competition between compart-
ments into theselection ofparametervalues.
This also provides a convenient way to
relate model parameters to data on the early
distribution of tracer lead. In the present
model, a deposition fraction, F, for a com-
partment other than the rapid turnover
compartment, EVF (which is assumed to
equilibrate with diffusible plasma within a
few minutes after injection of lead into
blood) indicates that the compartment
accumulates roughly 2 x Fx 100% of the
initial input to blood during the first hour
or so after injection. This is because com-
partment EVF is assigned a deposition frac-
tion of 0.5 and thus receives about halfof
the injected amount within minutes. This
initial inflow into EVF rapidly redistributes
to the other compartments, virtually dou-
bling the contents of those compartments
over a short time.
Volume 101, Number 7, December 1993 599Table 1.Age-specific transfer rates(perday) forthe model indicated in Figures 1 and 28
Pathwayb
Plasma-D to EVF
Plasma-D to RBCs
Plasma-D to Plasma-B
Plasma-D to Urinarybladderc
Plasma-D to Small intestined
Plasma-D toTrab surf
Plasma-D to Cortsurf
Plasma-D to Liver 1
Plasma-D to Urinary path
Plasma-D to Other kidney
Plasma-D to STO
Plasma-D to STI
Plasma-D to ST2
Plasma-D to Brain
Plasma-D to Sweat
RBCsto Plasma-D
EVFto Plasma-D
Plasma-B to Plasma-D
Cortsurfto Plasma-D
Trab surfto Plasma-D
Cortsurfto Exch vol
Trab surfto Exch vol
Cortexch volto Surf
Trab exch volto Surf
Cortexch volto Nonexch vol
Trab exch volto Nonexch vol
Cort nonexch vol to Plasma-D
Trab nonexch volto Plasma-D
Uver 1 to Plasma-D
Uver 1 to Small intestine
Liver 1 to Liver2
Liver 2to Plasma-D
Urinarypathto Urinary bladder
Otherkidneyto Plasma-D
STOto Plasma-D
STI to Plasma-D
STI to Excreta
ST2to Plasma-D
Brainto Plasma-D
0-100days I year 5years 10years 15years 2.25years
1000.0 1000.0 1000.0 1000.0 1000.0 1000.0
297.1 406.9 425.1 366.9 300.6 480.0
0.495 0.678 0.709 0.611 0.501 0.800
18.57 25.43 26.57 22.93 18.79 30.00
7.429 10.171 10.629 9.171 7.514 12.000
96.00 57.60 56.83 89.50 132.25 88.96
384.0 230.4 199.2 268.5 341.8 71.0
49.52 67.81 70.86 61.14 50.10 80.00
24.76 33.90 35.43 30.57 25.05 40.00
0.248 0.339 0.354 0.306 0.250 0.400
103.3 141.5 148.4 128.0 104.9 177.5
12.38 16.95 17.71 15.29 12.52 10.00
1.238 1.695 1.771 1.529 1.252 2.000
0.557 0.763 0.266 0.229 0.188 0.300
4.333 5.933 6.200 5.350 4.383 7.000
0.4620 0.4620 0.2770 0.1390 0.1390 0.1390
333.3 333.3 333.3 333.3 333.3 333.3
0.139 0.139 0.139 0.139 0.139 0.139
0.65 0.65 0.65 0.65 0.65 0.50
0.65 0.65 0.65 0.65 0.65 0.50
0.35 0.35 0.35 0.35 0.35 0.50
0.35 0.35 0.35 0.35 0.35 0.50
0.0185 0.0185 0.0185 0.0185 0.0185 0.0185
0.0185 0.0185 0.0185 0.0185 0.0185 0.0185
0.00462 0.00462 0.00462 0.00462 0.00462 0.00462
0.00462 0.00462 0.00462 0.00462 0.00462 0.00462
0.00822 0.00288 0.00154 0.00089 0.000512 0.0000822
0.00822 0.00288 0.00181 0.00132 0.000956 0.000493
0.0312 0.0312 0.0312 0.0312 0.0312 0.0312
0.0312 0.0312 0.0312 0.0312 0.0312 0.0312
0.00693 0.00693 0.00693 0.00693 0.00693 0.00693
0.00693 0.00693 0.00693 0.00190 0.00190 0.00190
0.139 0.139 0.139 0.139 0.139 0.139
0.00693 0.00693 0.00693 0.00190 0.00190 0.00190
2.079 2.079 2.079 2.079 2.079 2.079
0.00416 0.00416 0.00416 0.00416 0.00416 0.00416
0.00277 0.00277 0.00277 0.00277 0.00277 0.00277
0.00038 0.00038 0.00038 0.00038 0.00038 0.00038
0.00095 0.00095 0.00095 0.00095 0.00095 0.00095
'Uransfer ratesfor ages intermediate tothose addressed in Table 1 are obtained byinterpolating linearly
with age betweenthe listed rates. Forexample, atransfer ratefor age 4years is calculated as 0.25times
the rate given forage 1 year plus 0.75timesthe rate given for age 5years.
bPlasma-D and plasma-B are diffusible and bound plasma compartments; trab and cort indicatetrabecu-
larand cortical bone; surfand vol indicate bone surface and volume, and exch and nonexch indicate
exchangeable and nonexchangeable bone.
CFor mostpurposes, itsufficesto assume instantaneoustransferfrom urinary bladderto urine.
There is also assumed transferfromthe small intestine backto diffusible plasma. The assigned rate
depends onthe choice ofa gastrointestinal tract model (seeappendix).
Model for Adults
rapidly to the extravascular spaces and
Ciulation RBCs. A tiny fraction ofthe total outflow
Basisfor twoplasma compartments. Soon from diffusible plasma is assigned to a pro-
after introduction of a lead tracer (radi- tein-bound compartment of plasma that
olead) into blood plasma, the tracer is returns leadslowly to diffusible plasma and
largely available for diffusion into extravas- eventually contains most of the plasma
cular fluids and filtration by the kidneys lead.
(26-28). Under steady-state conditions, Totaltransfer ratefrom diffisibkplas-
however, most of the plasma lead appar- ma (to al destinations). Immediately after
endy is bound to proteins, with a-globu- intravenous injection of radiolead into
lin having a particularly high lead-binding adult humans, activity disappears from
capacity (29,30). Two plasma compart- blood at a rate of about 1/min
ments are needed to depict a gradual shift (27,31-33), which is similar to the rate
ofalarge portion ofplasma lead to nondif- determined for radiocalcium in human
fusible plasma proteins (Fig. 2). Lead subjects (34). The assigned transfer rate of
injected or absorbed into blood or return- lead from diffusible plasma to all destina-
ing to blood from the extravascular spaces tions should be somewhat higher than
is assigned to the diffusible compartment 1/min, however, to account for rapid
within plasma, from which it transfers uptake by RBCs (Fig. 3) as well as transfer
to the extravascular spaces (27,28,31). A
reasonable estimate of the total transfer
rate from diffusible plasma may be about
1.3- 1.4/min.
After conversion of units and round-
ing, the total removal rate from diffusible
plasma to all destinations is set at 2000/day.
As explained in a previous section, this
value is used to calculate transfer rates from
diffusible plasma to various compartments.
Basisfor representing RBCs as a single
compartment. The RBCs have a high affin-
ity for lead and contain nearly all of the
blood lead (BPb) under most conditions.
The blood concentration increases approx-
imately linearly with intake at relatively
low levels of intake but increases more
slowly with high levels of intake (17,18,
35). It has been found that the fraction of
BPb associated with plasma increases at
blood lead concentrations substantially
exceeding 25 1ig/dl, and that there is also a
nonlinear relation between lead in blood
and that in urine, bone, and other tissues
and fluids at such levels (17,36-38). As
discussed later, such nonlinear behavior of
lead at high levels of intake may result
largely from a reduced rate of flow from
plasma into RBCs as certain lead-binding
components of these cells become saturat-
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Figure 3. Model prediction (curves) and observa-
tions [circles; representing data from Cham-
berlain et al. (27)] of percent blood lead in plas-
ma, as a function of time after administration of
radiolead to adult human subjects by intravenous
injection or inhalation.
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ed. At least one of these components may
present a moving target ofsorts, in that its
formation may be induced to some extent
by prolonged exposure to high levels of
lead (39).
It appears, therefore, that a fairly
detailed process model of uptake and
retention of lead by RBCs would require
several compartments, with some being
saturable and at least one having an expo-
sure-dependent saturation level. At pre-
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Figure 4. Model predictions (curve) and observa-
tions [circles; representing data from Cham-
berlain et al. (21)1 of the blood content of radi-
olead as a function of time after intravenous
injection into adult human subjects.
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Figure 5. Model predictions (curve) and observa-
tions [circles; representing data from Hursh et al.
(42)1 of buildup of radiolead in red blood cells as a
function of time after inhalation by adult human
subjects.
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sent, there is not sufficient quantitative
information to derive transfer rates for
multiple compartments within RBCs. In
this model the RBCs are represented as a
single compartment in exchange with dif-
fusible plasma, but nonlinear kinetics is
imposed at relatively high concentrations
oflead in RBCs. That is, above a threshold
concentration oflead in RBCs, the transfer
rate from plasma to RBCs is assumed to
decrease as the concentration of lead in
RBCs increases.
Transfer rates between diffuibleplas-
ma andRBCs. A minimum blood content
ofabout one-third ofthe injected amount
is reached within 2-3 min (Fig. 4), at
which time roughly three-fourths of BPb
resides in RBCs (Fig. 3). The RBC content
then increases over a period of hours as
most of the systemically distributed lead
returns to plasma (31,40,41). By 1 day
after administration of radiolead to adult
humans, blood typically contains 55-60%
ofthe injected or absorbed amount (Figs. 4
and 5) 27,28,31,32,41-45). Over the next
several weeks, lead is lost from blood with
a net half-time on the order of 15-20 days
(Fig. 6) (9,27,28,32,46,47). As indicated
in Figure 7, longer net half-times and siz-
able intersubject variability are apparent at
times remote from exposure, when the
blood content may be determined as much
by the rate offeedback from bone and soft
tissues as bythe rate ofloss from RBCs.
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Available data on retention of tracer
lead in blood of human subjects can be
reproduced reasonably well by assuming
that the RBCs receive about a fourth ofthe
lead atoms leaving diffusible plasma (more
precisely, a deposition fraction of 0.24 is
assigned) and return lead to diffusible plas-
ma with a removal half-time of 5 days.
Thus, for low concentrations of lead in
RBCs, the transfer rate from diffusible
plasma to RBCs is 0.24 x (2000/day) =
480/day. As described later, the deposition
fraction for RBCs is assumed to decrease
when the concentration of lead in the
RBCs exceeds 60 pg/dl RBC, which corre-
sponds to about 25 pg/dl blood.
Transfer rates between diffsible and
boundplasma. The protein-bound fraction
ofplasmalead is not known, but it appears
to be considerablylarger than the diffusible
fraction under steady-state conditions
(26,29,30,37,48). After parameter values
for diffusible plasma and RBCs are set, rea-
sonable estimates ofthe transfer rate from
diffusible plasma to protein-bound plasma
and ofthe removal half-time from protein-
bound plasma lead can be inferred from
data on 1) the time-dependent division of
radiolead between RBCs and plasma, 2)
the steady-state division of lead between
RBCs and plasma, and 3) the ultrafilter-
able fraction ofplasma lead.
Data on healthyhuman subjects receiv-
ing radiolead by injection or inhalation
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Figure 6. Model predictions (curve) and observa-
tions vertical lines; indicating range of values
reported in Chamberlain et al. (27)] of decline of
lead content of blood as a function of time after
injection of radiolead into adult human subjects.
Predictions and observations have been normal-
ized to 100% at2.5 days.
Figure 7. Model predictions (curves) and observations [circles; representing data from Rabinowitz et al.
(9)] oflead content ofblood ofadult human subjects as a function oftime after beginning of controlled
ingestion ofan isotope oflead. Ingestion periodsfor subjects A, B, and D were 104, 124, and 83 days,
respectively; subject E ingested the lead tracerfor8 days and again on days 42-51 afterthe initial intake.
The gastrointestinal absorption fractions assujed forsubjects A, B, D, and Ewere 0.10,0.07,0.12, and
0.09, respectively, as derived by Rabinowitz and co-workers (9) and adjusted by Chamberlain etal.(27).
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601indicate that the RBCs contain 95-99% of
the blood content ofradiolead at 0.5-1 hr
after injection (31,33), more than 99% at
3 hr after injection (31), more than 99.5%
at 10 hr or more after injection or inhala-
tion (27), and about 99.8% at 50-100 hr
after injection (2$). Experimental determi-
nations of the time-dependent division of
lead between RBCs and plasma in human
subjects are shown in Figure 3 (27). Such
findings for humans are reasonably consis-
tent with modern data on laboratory ani-
mals. For example, more than 99% of
2i0Pb in blood was associated with RBCs
by 1 hr after injection ofthis isotope into
beagles (49); about 99.8% of 21 Pb in
blood was found in RBCs of adult mon-
keys at 96 hr after oral intake of this iso-
tope (50); and nearly 99.8% of2l0Pb in
blood was associated with RBCs by 1 day
after injection into rabbits (51). In rats,
plasma may contain as much as 2% of
BPb, even at lowblood lead levels (20,52).
The division of lead between RBCs
and plasma ofchronically exposed humans
or laboratory animals has not been dearly
established, mainly because ofthe difficul-
ty in measuring the typically low concen-
tration in plasma and the possibility of
cross-contamination from RBCs (27,53).
Another complicating factor is that (as dis-
cussed later) there is a nonlinear relation-
ship between the plasma lead and blood
lead concentrations, at least when the lat-
ter greatly exceeds 25 pg/dl (17,18,
36-38). According to the ICRP (54), plas-
ma lead accounts for about 10% ofblood
lead at equilibrium, but more recent esti-
mates are in better agreement with the
lower percentages suggested by relatively
short-term studies with radiolead. Data of
Cavalleri et al. (55) and deSilva (53) indi-
cate that plasma may contain roughly
1-2% of blood lead for a wide range of
exposure levels. Measurements of Everson
and Patterson (56) suggest that plasma
contained only about 0.01% of BPb in a
typically exposed person and about 0.15%
in a person with a high exposure. Manton
and Cook (37) estimated that plasma con-
tains roughly 0.2% ofBPb at an equilibri-
um blood lead concentration of 10 pg/dl
and as much as 2% at a concentration of
100 pg/dl. Measurements of Minoia and
co-workers (57) on a large number ofsub-
jects with no occupational exposures indi-
cate that plasma may contain roughly
0.1% of BPb. The present model is de-
signed to yield an equilibrium plasma lead
content of 0.2% of BPb for low levels of
lead intake (but higher percentages for ele-
vated intakes), since this value is suggested
by studies on humans administered radi-
olead and is reasonably consistent with
recent measurements of stable lead in
humans.
Results of renal clearance studies on
dogs receiving either a single injection or
continuous infusion ofradiolead suggest a
gradual decrease with time in the ultrafil-
terable portion ofplasma lead (26). These
results, together with renal clearance data
on chronically exposed human subjects
(37,48), indicate that the ultrafilterable
portion ofplasma lead during continuous
intake may be in the range 5-30%, with
perhaps 15% beingtypical.
Transfer rates between diffusible and
bound plasma lead were set for agreement
with 1) data on the early division of radi-
olead between plasma and RBCs, 2) exper-
imental determinations of urinary clear-
ance ofplasma lead (discussed later), 3) the
estimate that plasma lead represents 0.2%
ofBPb at equilibrium, and 4) the estimate
that 15% ofplasma lead is ultrafilterable at
equilibrium. The deposition fraction in the
bound plasma compartment is set at
0.0004, yielding a transfer rate of 0.0004
x (2000/day) = 0.8/day from diffusible to
bound plasma. The assigned removal half-
time from bound to diffusible plasma is 5
days, which is of the same order as the
half-life ofplasma proteins (5$).
Basisfor the EVFcompartment. After
intravenous injection of lead, the blood
concentration is rapidly reduced by trans-
fer from plasma to other extracellular flu-
ids, but the simultaneous transfer from
plasma to RBCs reverses the gradient with-
in a few minutes and brings back a sub-
stantial portion of extravascular lead to
blood (28,31,40,41). Compartment EVF
is used to model this rapid feedback oflead
from extravascular spaces. This compart-
ment is assumed to exchange lead only
with diffusible plasma. Lead that moves
from plasma to extravascular fluids to
retention sites in tissues is treated as if it
passed direcdy from plasma to those reten-
tion sites and thus, in effect, is regarded as
passing instantaneously through the EVF
(Fig. 2). This treatment of the EVF as a
satellite compartment rather than a central
feeding compartment allows the user who
is not interested in the early kinetics of
lead to eliminate the EVF compartment
without altering transfer rates for other
compartments.
Tranfer rates betwe dWibleplarma
andEVF. The deposition fraction for EVF
is set at 0.5 to reproduce the early rapid
returnoflead to plasmafrom theextravascu-
lar spaces. Thus, the transfer rate from dif-
fusible plasma to EVF is 0.5 x (2000/day) =
1000/day. The transfer rate from EVF back
to diffiisible plasma is assumed to be one-
third as great, or 333.3/day, this is derived
from the postulate that the EVF compart-
ment contains three times as much lead as
diffusible plasma at equilibrium, which is
suggested by kinetic analysis ofplasma dis-
appearance curves for isotopes ofthe alka-
line earth elements. Forexample, Hart and
Spencer (34) estimated from measure-
ments on humans injected with radiocalci-
um that the volume of the rapidly ex-
changing extravascular fluids is about 3
(2.4-4.5) times the volume of the plasma
pool. Similarly, Harrison and co-workers
(59) conduded from measurements on an
adult male subject that intravenously
injected radioisotopes of calcium, stron-
tium, barium, and radium were rapidly
dispersed into an extravascular pool about
three to four times the size ofplasma.
Bone
Similarities between leadandthe alkaline
earth elements in bone. It has been recog-
nized for many years that lead follows the
movement of calcium in the body to a
large extent and thatphysiologic regulators
of calcium metabolism usually affect the
behavior of lead in a qualitatively similar
fashion (60-64). A particularly close
resemblance between these two elements
has been observed with regard to their
behavior in bone. It has been found that
lead competes with calcium for deposition
in bone and distributes similarly to calci-
um and other alkaline earth elements
amongdifferent bones and between trabec-
ular and cortical bone structures (49,60-
62,65). Bone lead may remain more mo-
bile than bone calcium for some time after
deposition (66,67), but data on humans
and laboratory animals indicate that long-
term skeletal distribution and retention are
similar for lead and the alkaline earth ele-
ments (49,68-71). In human cadavers, the
lead concentration was closely related to
the calcium concentration in bone biopsy
samples, despite the nonuniform distribu-
tion of lead found in the skeleton (72).
Lead has been used frequently as a marker
ofbone growth and osteon formation, and
a close resemblance in the patterns of
deposition oflead and calcium in forming
osteons has been demonstrated (73-77).
Lead is incorporated into the crystalline
structure ofbone, where itreplaces calcium
ions at some sites (78-81). Burial of lead
beneath surfaces in regions ofbone forma-
tion has been observed, and there is evi-
dence that lead is eventually distributed
throughout the bone volume (73-77,
82-86).
Similarities between lead and calcium
are also evident with regard to bone cell
metabolism. Asignificant fraction ofcellu-
lar lead in bone is rapidly exchangeable
and is modulated by the same ions and
hormones that regulate bone calcium
metabolism (87-8_). However, high con-
centrations oflead in bone leads to damage
to bone cells and interference with bone
remodeling (90).
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Structure ofthe bone modeL Based on
the qualitatively similar behaviors of lead
and the alkaline earth elements with regard
to bone, a bone model structure originally
developed for application to the alkaline
earth elements (22,91) is applied here to
lead. As far as practical, parameter values
are developed on the basis of lead-specific
data, but appeal is made to the alkaline
earth analogy wherever data on lead are
lacking.
The model structure is an updated ver-
sion of the long-standing alkaline earth
model for adult humans described in ICRP
Publication 20 (92). This new version has
been adopted bythe ICRP forconsideration
ofthe age-specific biokinetics ofcalciumlike
elements. As in the ICRP's earlier model
(92) for alkaline earth elements: 1) bone is
divided into four primary parts: cortical sur-
face, cortical volume, trabecular surface, and
trabecular volume; 2) the rapidly exchange-
able material in bone is assumed to reside
on bone surfaces, meaning endosteal and
periosteal surfaces ofcortical bone, surfaces
ofhaversian and Volkmann canals, surfaces
ofresorption cavities, and surfaces oftrabec-
ular bone. Bone surfaces do not indude the
surfaces oflacunae or canaliculi and should
not be confused with the surfaces of the
sub-microscopic bone crystals; 3) the more
slowly exchangeable material in bone is
assumed to reside in bone volume; 4) long-
term loss from bone is associated primarily
with bone resorption. In contrast to the
ICRP's earlier model for alkaline earth ele-
ments: 1) redeposition ofmaterial removed
from bone compartments is treated explicit-
lyand 2) material is assumed to be removed
from all bone compartments by first-order
processes.
The ICRP's earlier alkaline earth model
is a catenary (non-recycling) model involv-
ing a power-function component that
accounts for most ofthe biological removal
from bone volume occurring from a few
weeks to several months after injection (92).
This intermediate-term loss from bone is
generally ascribed to "diff-usion" ofmaterial
into osteons and/or ionic exchange ofa por-
tion ofthe element in deep bone with shal-
low bone pools or plasma calcium and has
been incorporated into some biokinetic
models for lead (15,20). Actually, the
processes giving rise to intermediate-term
loss from bone have not been dearly estab-
lished, either for lead or for the alkaline
earth elements. For lead, much of the loss
from bone occurring from a few days to a
year or more after exposure might result in
part from the bone diffusion process gener-
ally hypothesized and in part from other
processes, such as turnover oflead-binding
components of the organic matrix of bone
(93) or gradual release oflead from cellular
components ofbone.
Whatever the processes, the existence
of intermediate-term loss of lead from
bone is indicated by data on laboratory
animals injected with radiolead (15,20,49,
71,82,94). Also, the hypothesis that a sub-
stantial portion of bone lead remains
exchangeable for some time after exposure
is consistent with data on persons who
have received chelation therapy after expo-
sure to lead (95), although it must be con-
sidered that high concentrations of lead
may have changed the kinetics of lead in
bone.
In the present model, cortical and tra-
becular bone volume are each viewed as
consisting of two pools, referred to as the
exchangeable and nonexchangeable pools
(Fig. 1). The exchangeable bone volume
pool is identified with intermediate-term
loss from bone, meaning loss not associat-
ed with rapid exchange with plasma or
slow loss by bone resorption. Calciumlike
elements moving from bone surfaces to
bone volume are assumed to enter the
exchangeable pool and to leave this pool
with an element-specific half-time (a few
weeks or months). Part of the material
leaving exchangeable bone volume is
assumed to return to rapidly exchanging
bone surfaces and part is assigned to the
nonexchangeable bone volume, from
which it is assumed to be removed to plas-
ma only by bone resorption. The rate of
removal from nonexchangeable bone vol-
ume is equated with the rate of bone
turnover and is independent of the calci-
umlike element considered. The parameter
values assigned to exchangeable bone vol-
ume and bone surfaces are assumed to
include any effects ofbone resorption.
The assumptions that 1) bone lead is
rapidly exchangeable if and only if it
resides on bone surfaces, 2) bone volume is
in exchange with bone surfaces and not
plasma, and 3) all lead reaching bone vol-
ume is initially available for exchange are,
at best, only partially accurate. The trilay-
ered model of bone is intended only to
approximate the net result of the various
processes involved in the time-dependent
uptake and removal of lead from bone,
using first-order kinetics and a minimal
number of compartments. This layered
structure is consistent with a qualitative
model proposed by Rabinowitz (95), who
suggested that not all bone lead is equally
exchangeable with blood but has varying
degrees of accessibility until penetrating
the crystal surface, after which it becomes
firmly buried and must await osteoclastic
turnover.
Rates ofuptake and loss by bone sur-
faces. The net rate of exchange between
diffusible plasma and rapidly exchanging
regions ofbone (assumed to be at the bone
surfaces) and the amount of lead initially
retained in bone can be inferred from gen-
erally consistent data on healthy adult male
humans (28), baboons (82), and beagles
(49) injected with radiolead. These data
indicate that the adult skeleton accumu-
lates about 10-15% of intravenously
injected lead within a few hours. This
rapid uptake may be followed by a decline
in the bone content over the first day or
two after injection and then a gradual
increase over a period of weeks as lead
returns from RBCs and soft tissues to plas-
ma and accumulates in regions of bone
with slower loss. By 3-A weeks after injec-
tion, bone contains roughly 25% of the
administered amount (Fig. 8). These data
can be reproduced reasonably well if it is
assumed that 1) the deposition fraction on
all bone surfaces is 0.08. (Derivation of
transfer rates from diffusible plasma to the
individual bone surface compartments
requires additional information, discussed
below, on the initial division of lead
between trabecular and cortical bone); 2)
lead is removed from each bone surface
compartment at a rate of 1/day, with half
ofthe removed lead returning to diffusible
plasma and halfmigrating to sites in bone
with longer retention (exchangeable bone
volume). Thus, the transfer rate from tra-
becular or cortical bone surface to dif-
fusible plasma is 0.5/day, and the transfer
rate from trabecular or cortical bone sur-
face to the corresponding exchangeable
bone volume compartment is also 0.5/day.
Injection data on a variety of animal
species (60,62,82,96) indicate that the
concentration of lead is initially much
higher in trabecular bone than in cortical
bone. McLean and co-workers (62) found
that the concentration of radioactive lead
in trabecular bone ofdogs was at least five
times higher than that in cortical bone
soon after injection. This seems consistent
with limited biopsy data on human sub-
jects ingesting a lead isotope tracer over a
period of months (Table 2), when it is
considered that the samples of cortical
bone were almost entirely bone tissue, and
the trabecular samples probably contained
about twice as much soft material as bone
tissue, by mass (M. Rabinowitz, personal
communication; 18). Since the biopsies
were taken more than 3 months after the
beginning ofexposure, some redistribution
ofbone lead is likely to have occurred.
The initial division oflead between tra-
becular and cortical bone appears to be
similar to that of the alkaline earth ele-
ments [compare, for example, results of
McLean et al. (62) for lead in dogs with
results ofNorrdin and Arnold (65) for cal-
cium in dogs]. As assumed earlier for the
alkaline earth elements (91,97), the rate of
transfer of lead from diffusible plasma to
trabecular and cortical bone surfaces is
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addition rate ofthe given bone type. Since
there is roughly four times as much cortical
bone as trabecular bone by mass in the
adult human (54), and the rate ofaddition
of calcium per gram bone is on the order
of five to six times higher in trabecular
than cortical bone as an average over all
adult ages (91,97-), the rate of transfer of
lead from diffusible plasma to trabecular
surfaces is estimated to be 1.25 (5/4) times
higher than that to cortical surfaces in the
adult. Since the deposition fraction for all
bone surfaces of the adult is estimated as
0.08, the transfer rate from diff-usible plas-
ma to trabecular bone surfaces is
(1.25/2.25) x 0.08 x (2000/day)=
88.9/day
and the transfer rate from diffusible
plasma to cortical bone surfaces is
(1.00/2.25) x 0.08 x (2000/day)=
71.1i/day.
Rates oflossfrom the exchangeable
bone volumecompartments. Parameter val-
ues for the exchangeable bone volume
compartments are based on 1) data on
retention of 2bm af in whole bodies and
bones ofbaboons (82) and beagles (15,49,
94); 2) the fraction of total-body lead in
bone of chronically exposed humans; 3)
apparent similarities between lead and
radium with regard to intermediate- and
long-term retention in bone; and 4) the
assumption that the transfer ratcsto and
from exchangeable bone volume are the
same for trabecular as for cortical bone.
The data on baboons and beagles suggest
that most of the peak content of lead in
bone is removed from the body within a
few months. Data on humans chronically
exposed to lead, summarized in a later sec-
tion, are consistent with the assumption
that a relatively small portion (on the order
of 20%) of lead entering bone volume is
retained over an extended period. The
inferred pattern of translocation of lead
from exchangeable bone volume is broadly
similar to that described earlier for radium
(91). Byanalogywith radium it is assumed
that the removal half-time of lead from
exchangeable bone volume is 30 days, that
20% of lead leaving exchangeable bone
volume moves to nonexchangeable bone
volume, and that 80% returns to bone sur-
faces. Thus, the transfer rate from the
exchangeable to the nonexchangeable bone
volume compartment of either trabecular
or cortical bone is 0.2 x 0.693/(30 days) =
0.00462/day and from exchangeable bone
volume to bone surface is 0.8 x 0.693/(30
days) = 0.0185/day.
Rates oflossfrom nonexchangeable
bone compartments. Studies of beagles
injected with radioisotopes oflead, radium,
or strontium indicate that skeletal reten-
tion is similar for these elements, particu-
larly after a few weeks, and that their rate
of removal from the skeleton after a few
months may be largely controlled by the
rate of bone resorption (49,71). As in an
earlier model for the alkaline earth ele-
ments (22,91), it is assumed that the rate
of removal of lead from nonexchangeable
bone volume is the same as the rate of
bone turnover and that lead leaving nonex-
changeable bone volume enters diffusible
plasma. The age-specific bone turnover
rates given in Table 1 are those developed
in an earlier paper (97) and adopted by the
ICRP (21). These values are based on his-
tomorphometric measurements on human
subjects and studies ofretention ofcertain
bone-seeking radionudides in human sub-
jects. Most histomorphometric measure-
ments are on ribs and iliac crest, but there
Table 2 Measurements and model predictions of
the concentration (pg/g) of lead in biopsied iliac
bone from human subjects ingesting a lead iso-
topetracer overa period ofmonths"
Observed/this model
SubjectA SubjectB
Bonetype dayll6 daylO5
Trabecular 0.075/0.097 0.045/0.060
Cortical 0.049/0.058 0.054/0.036
°Data are from Rabinowitz et al. (9). The concen-
trations are expressed on a fresh-weight basis.
The observations indicate considerably greater
concentrations of lead in trabecular than cortical
bonetissue at 105-116daysfrom the beginning of
exposure because trabecular biopsy samples
generally contain more soft material than bone
tissue by mass. Model predictions are based on
the assumption that the cortical samples repre-
sent 4000 g of bone tissue and the trabecular
samples represent 1000 g of bonetissue plus 2000
g ofsoftmaterial.
are also a few measurements for various
long bones. It is assumed that there are no
differences in turnover rates ofcortical and
trabecular bone early in life but that differ-
ences gradually appear during childhood
and eventually grow to about a factor of6
in the mature adult. Differences with age
in bone turnover during adulthood (23,24,
97) are not addressed here.
Several authors have attempted to iden-
tifya single, long-term turnover rate oflead
in the adult human skeleton. Estimates
have been based on animal studies, the rate
ofbone remodeling, balance considerations
regarding 21Pb or stable lead, the decline
ofBPb after the end ofoccupational expo-
sure, and in vivo measurements of the
decline of21OPb or stable lead in bone after
elevated exposures (4698-107). Estimates
have ranged from about 0.007/year to
about0.15/year.
Cohen and co-workers (107) used in
vivo measurements over the skull and uri-
nary excretion measurements to estimate
the rate of decline of210Pb (radiological
T1/2 = 22.3 years) in a subject contaminat-
ed with this radionuclide 33 years before
the initial measurements in 1980. They
estimated from in vivo measurements that
the total-body content was 9.55 kBq in
1980 and 5.88 kBq in 1990. Ifexponential
decline is assumed, these initial and final
estimates would indicate a biological
removal rate of0.017/year. Ifthree in vivo
measurements made between 1980 and
1990 are induded and a best exponential
fit to the five measurements is derived, a
biological removal rate of only 0.007/year
is obtained. If it is assumed that urinary
excretion represents 55-60% of total
excretion of lead at times remote from
exposure (see the section on excretion), the
urinary excretion measurements (taken in
1990) indicate a biological removal rate of
0.021-0.023/year. The present model pre-
dicts that a total-body burden of9.55 kBq
of210Pb remaining after an acute intake 33
years earlier would decline to 5.15 kBq
after 10 more years, and that the biological
removal rate from the total body at 43
years would be about 0.027/year (ifmodel
predictions for 42-44 years are approxi-
matedbyasingle exponential function).
Christoffersson and co-workers (108)
used in vivoX-ray fluorescence to measure
the decline oflead in finger bone in former
lead workers. For eight subjects followed
for up to 5 years, a biological half-time of
6.7 (range 3-15) years was estimated. In a
second group ofsix persons followed from
year 7 to year 13 after finishing lead work,
a half-time of 8.2 (range 2-oo) years was
estimated. There was generally good agree-
ment between the estimated decine oflead
in finger bone and the dedine in blood of
these subjects (106,108). Based on these
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data and additional measurements of lead
in bone biopsies (vertebrae), blood, and
urine of present or former lead workers,
Skerfving et al. (106) concluded that the
skeletal lead pool is not kinetically homo-
geneous, that turnover of lead is faster in
the mainly trabecular vertebrae than in the
mainly compact finger bone, and that the
"average over-all half-time is probably
5-10 years."
Only broad comparisons between
model predictions and findings of Chris-
toffersson, Skerfving, and co-workers can
be made due to the paucity ofinformation
on the lead exposures experienced by the
subjects. The model does not predict a sin-
gle biological half-time for bone after an
extended elevated exposure; rather, the rate
ofloss from the total skeleton is predicted
to decrease gradually as the fraction of
bone lead in nonexchangeable cortical
bone increases. Also, the rate of decline
depends somewhat on the pattern and
duration of the exposure, which affect the
distribution of bone lead at the end of
exposure. For presumably realistic occupa-
tional exposure scenarios, the predicted
decline in total bone lead after the end of
exposure corresponds to a half-time on the
order of 10-12 years during the first few
years after exposure and roughly 25 years
at 25-30 years afterexposure.
Liver: Model Structure and Transfer
Rates
The liver and kidneys are treated separately
from other soft tissues because of their
importance as excretion pathways for lead
and because they show substantially higher
concentrations oflead than most soft tis-
sues.
Data on injected lead in human sub-
jects (28), baboons (82), and beagles (495)
indicate that the liver rapidly accumulates
10-15% ofsystemic lead and loses much
of this within a few weeks. In chronically
exposed adult humans, the liver may con-
tain about 2-3% of total-body lead, and
the blood-to-liver lead concentration ratio
is about 0.2 (54,109-115). Part ofthe loss
oflead from liver can be accounted for by
biliary secretion into the gastrointestinal
contents (9,116), but return ofa consider-
able portion of liver lead to blood must
also be postulated due to the limited losses
of lead in feces. Since the level of biliary
secretion of metals varies considerably
from one species to another (117), quanti-
tative information on biliary secretion of
lead by laboratory animals (particularly
rodents) is oflimited value for present pur-
poses.
In this model the liver isviewed as con-
sisting of two compartments. A compart-
ment with relatively high uptake from
plasma and a relatively short removal half-
time (several days) is needed to help repro-
duce the pattern of uptake and decline of
lead observed in human subjects, baboons,
and beagles during the first fewweeks after
intravenous injection. An additional liver
compartment with much smaller uptake
but with gradual build-up of lead over a
period ofyears is then needed to reproduce
the blood-to-liver concentration ratio
determined from data on chronically
exposed human subjects. The two liver
compartments are referred to as liver 1 and
liver 2.
Available data on hepatic uptake and
retention oflead in humans and laboratory
animals and on biiary secretion oflead in
humans can be reproduced reasonably well
with this two-compartment model and the
followingassumptions: 1) ofleadleavingdif-
fusible plasma, 4% deposits in liver 1. Thus,
the transfer rate from diffusible plasma to
liver 1 is 0.04 x (2000/day) = 80/day, 2) the
removal half-time from liver 1 is 10 days. Of
lead leaving liver 1, 10% moves to the long-
term retention compartment (liver 2), 45%
enters the contents ofthe small intestine via
biliary secretion, and 45% returns to dif-
fiusible plasma. Thus, the transfer rate from
liver 1 to liver 2, for example, is 0.1 x
0.693/(10 days) = 0.00693/day. Lead enter-
ing the contents of the small intestine in
liver bile is assumed to follow the same
kinetics as ingested lead (see appendix); 3)
the removal half-time from liver 2 is 1
year. All lead leaving liver 2 is assumed to
return to diffusible plasma.
Model predictions are reasonably con-
sistent with data on chronically exposed
adult humans indicating that the liver may
contain roughly 2-3% of total-body lead.
Also, the model predicts a blood-to-liver
lead concentration ratio of 0.2 for the
chronically exposed adult, in agreement
with the data on adult humans. Model
predictions of the adult liver content of
lead during the first several weeks after
injection are compared in Figure 9 with
data on human subjects, baboons, and bea-
gles injected with radiolead. The observa-
tions for human subjects indicated in
Figure 9 are only semiquantitative esti-
mates based on external measurements.
The liver content in baboons or beagles at
1-2 months is expected to provide only a
lower-bound estimate for humans because
the lead contents in the total body and
blood (and presumably all compartments
with relatively high turnover rates) dedine
faster in those animals than in humans
(28,49,8X.
Kidneys: Model Structure and
Transfer Rates
Results of studies on dogs and rodents
indicate that the kidneys may accumulate
as much as 15-20% of intravenously
injected radiolead within the first 1-2 hr,
that the preponderance of the deposited
activity represents filtered lead, and that a
substantial portion of the early accumula-
tion is reabsorbed or lost in urine within a
few hours (118-120). In rats, the kidneys
contained roughly 10% ofthe intravenous-
ly injected amount after 1 daybut less than
2% after 9 days (82). In baboons receiving
radiolead by intravenous injection, the kid-
neys contained roughly4% ofthe adminis-
tered amount after 1 day, 0.6% after 30
days, and 0.1% after 60 days (82). Com-
parison ofthe decline ofrenal and hepatic
activity over the first two months in these
baboons indicate a half-time in the kidneys
that would be roughly one-half of that in
the liver, ifeach ofthese organs were con-
sidered as a single compartment. This
agrees with estimates of Mallon (13) for
baboons exposed to lead by daily ingestion
over a period of a few months. In dogs
receiving 210Pb by intravenous injection,
the kidneys contained about 0.5% of the
administered activityat 1 month (49).
In this model the kidneys are viewed as
consisting oftwo compartments, one with
relatively high deposition but short reten-
tion of lead and one with relatively low
uptake but long retention. These compart-
ments are referred to as the "urinary path"
(UP) and "other kidney tissue" (OKT),
respectively. Both are assumed to receive
lead from diffusible plasma. Material
removed from UP moves to the urinary
bladder contents, and that removed from
OKT returns to diffusible plasma. Com-
partment UP is needed to reproduce an
early rapid buildup and fairly fast (days)
decline oflead in the kidneys as indicated
by data on laboratory animals, as well as
the early (2-week) pattern of decline of
lead in urine as indicated by data on
human subjects injected with radiolead.
Compartment OKT is needed to repro-
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Figure 9. Model predictions and observations of
the lead content of the adult liver as a function of
time after intravenous injection. The observation
curve for humans is based on external measure-
ments on adult human subjects intravenously
injected with 23Pb (28). The data point for bea-
gles isfrom Lloyd et al. (49), and data for baboons
are from Cohen etal.(82).
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lead concentration ratios observed in
chronically exposed persons. No attempt is
made to quantify separately the rates of
glomerular filtration, tubular absorption,
and tubular secretion, all ofwhich appar-
ently occur for lead (26,119,121). Rather,
movement of lead from diffusible plasma
into the kidney compartments and urinary
bladder contents is described only in terms
ofthe net result ofthese three processes.
The parameter values for the UP com-
partment ofthe kidneys were based largely
on the data for laboratory animals summa-
rized above but were adjusted for consis-
tency with time-dependent urinary excre-
tion rates observed in human subjects
acutely exposed to radiolead (see the dis-
cussion of the parameter values describing
urinary excretion). No attempt was made
to reproduce the rapid accumulation and
decline of lead in the kidneys that occurs
in the first hour or two after injection.
It is assumed that 2% of lead leaving
diffusible plasma deposits in the urinary
path compartment, UP, yielding a transfer
rate from diffusible plasma to UP of 0.02
x (2000/day) = 40/day. The removal half-
time from UP to the urinary bladder con-
tents is assumed to be 5 days, correspond-
ing to a transfer rate of 0.693/(5 days) =
0.139/day.
After the parameter values for the uri-
nary path compartment were selected,
those describing uptake and removal by
the OKT compartment (which represents
tenacious retention in the kidneys) were set
for consistency with estimated relative lead
contents in liver and kidneys of human
subjects chronically exposed to lead. That
is, parameter values for this compartment
were set to account for the difference
between the total kidney content and the
content of the urinary path compartment
during chronic exposure.
It is assumed that the OKT compart-
ment receives 0.02% of lead leaving dif-
fusible plasma (amounting to about 1% of
the total deposition in the kidneys). Thus,
the transfer rate from diffusible plasma to
OKT is 0.0002 x (2000/day) = 0.4/day.
The removal half-time from OKT to dif-
fusible plasma is assumed to be 1 year, cor-
responding to a transfer rate of0.693/(365
days) = 0.0019/day.
The model predicts that the kidneys of
the adult would contain almost 5% of
intravenously injected lead after 1 day,
almost 2% after 1 month, and almost 1%
after 2 months. The model was designed to
overestimate observed kidney contents in
baboons and beagles at 1-2 months be-
cause the content oflead in blood and the
total body decline faster in those animals
than in humans.
Brain: Model Structure andTransfer
Rates
The brain is considered explicitly in this
model because ofits high sensitivity to lead
as a chemical toxin. Lead is distributed
unevenly in the brain, with the distribu-
tion depending to some extent on the level
ofexposure. At low levels, the lead concen-
tration in different regions of the human
brain is significantly correlated with the
potassium concentration, indicating that
lead is mostly accumulated in cell-rich
parts ofthe brain such as the hippocampus
(122-124). As with other types of cells,
lead entering brain cells apparently is taken
up rapidly by mitochondria, accumulating
predominantly in those regions where cal-
cium localizes (87). At very high levels,
lead gains access to neural tissue following
breakdown of the blood-brain barrier
(124). In cases oflead poisoning in young
children, the lead concentration of the
brain becomes extremely high and may
approach or even exceed that of the liver
and kidney (125,126).
It appears, therefore, that a fairly
detailed model of the behavior of lead in
the brain would require multiple compart-
ments and consideration of nonlinear
kinetics. Due to limitations in kinetic data,
however, the brain is treated here as a sin-
gle compartment that exchanges lead slow-
ly with diffusible plasma, and linear kinet-
ics is assumed.
Data on baboons, dogs, and rodents
indicate that the brain has low uptake but
tenacious retention oflead (49,82,120). In
young adult female baboons intravenously
injected with 2loPb, the brain contained
about 0.04% ofthe administered lead at 1
day but continued to accumulate activity
released by other organs, showing about
0.07% after 30 days and 0.08% after 60
days (82). In beagles the brain contained
0.04% of injected 21 Pb at 1 month after
injection and <0.003% at 3-4 years.
An assumed deposition fraction for
brain of 0.00015 [corresponding to a
transfer rate from diffusible plasma to
brain of0.00015 x (2000/day) = 0.3/day]
and a removal half-time of 2 years yield
predictions that are reasonably consistent
with injection data for large laboratory ani-
mals and with autopsy data for occupa-
tionally as well as environmentally exposed
adult humans. The model predicts that the
adult brain contains 0.04% of adminis-
tered lead at 1 day and 0.13% at 60 days
after injection and gradually increases to a
peak content of0.15% at 6 months.
Other SoftTissues: Model Structure
andTransfer Rates
The remaining soft tissues, consisting of
skeletal muscle, fat, skin, and a variety of
small organs and tissues, represent most of
the body's mass but only a small percent-
age of its lead content in the chronically
exposed adult. Data on laboratory animals
administered radiolead indicate that initial
deposits of lead in skeletal muscle and
other massive soft tissues are largely deared
by 1 day after administration and that
these tissues probably account for no more
than 3-4% of the absorbed amount after
that time (49,52,82,94,119,122). There
are indications, however, thatsmall amounts
are tenaciously retained in skeletal musde,
aorta, and perhaps other soft tissues
(49,82).
In this model the other soft tissues are
assumed to consist ofthree compartments,
STO, STI, and ST2, representing a wide
range of turnover rates. These compart-
ments are based primarily on kinetic con-
siderations and cannot be given precise
anatomical definitions.
Compartment STO is assigned a high
turnover rate and, together with bone sur-
faces, accounts for most of the feedback
from extravascular spaces to plasma occur-
ring from about 30 min (when compart-
ment EVF is virtually depleted) to a few
days after acute intake. Based on the blood
"reappearance" curve for lead during the
first day and considerations of mass bal-
ance ofthe deposition fractions in different
organs, it is assumed that STO receives
almost 9% (precisely, 8.875% to achieve
mass balance of deposition fractions) of
lead leaving diffusible plasma and loses
lead to diffusible plasma with a removal
half-time of 8 hr. Thus, the transfer rate
from diffusible plasma to STO is 0.08875 x
(2000/day) = 177.5/day and from STO to
diffusible plasma is 0.693/(0.333 day) =
2.08/day. 210
In beagles injected with Pb, soft tis-
sues other than liver, kidneys, and brain
contained about 3% of the injected
amount at 28 days and less than 0.2% at
1100 days (49,94). Most ofthe other soft
tissue content at 28 days was found in pelt.
In this model, compartment ST1 is used to
depict such intermediate-term loss (i.e., a
few weeks or months) from other soft tis-
sues and also serves as the source ofloss of
lead from the body in substances other
than urine, feces, and sweat (e.g., hair,
nails, and desquamated skin). The deposi-
tion fraction for ST1, the total removal
half-time from STI to diffusible plasma
and excreta, and the division of outflow
between diffusible plasma and excreta were
chosen for broad consistency with data on
intermediate-term retention oflead in soft
tissues of laboratory animals and data on
the rate of loss of lead in hair, nails, and
skin of human subjects (9). It is assumed
that STi receives 0.5% of lead leaving dif-
fusible plasma. The total removal half-time
from STI is assumed to be 100 days, with
Environmental Health Perspectives 606- -. . - - 9I I 9
60% of the outflow returning to diffusible
plasma and 40% lost in hair, nails, and
desquamated skin. Thus, the transfer rate
from diffusible plasma to STI is 0.005 x
(2000/day) = 10/day, the transfer rate from
STI to diffusible plasma is 0.6 x 0.693/(100
days) = 0.00416/day, and the transfer rate
from STI to excreta is 0.4 x 0.693/(100
days) = 0.00277/day.
Compartment ST2 represents tena-
cious retention of a small amount of lead
in soft tissues and is used to account for
most of the lead in massive soft tissues of
chronically exposed humans. To avoid a
gross overestimate of data for beagles
injected with 210Pb, it must be assumed
that no more than 0.1% of the injected
amount is deposited in a soft-tissue com-
partment with a retention time of years.
Then, in order for compartment ST2 to
gradually accumulate the level oflead indi-
cated by autopsy data on chronically
exposed humans, it must be assumed that
the removal half-time from compartment
ST2 is at least 5-10 years. It is assumed
here that compartment ST2 receives 0.1%
of outflow from diffusible plasma and
returns lead to diffusible plasma with a
removal half-time of 5 years. The transfer
rate from diffusible plasma to ST2 is 0.001
x (2000/day) = 2/day and the transfer rate
from ST2 to diffusible plasma is
0.693/(1825 days) = 0.00038/day.
The model predicts that the three other
soft tissues, STO, ST1, and ST2 combined,
contain 6% of intravenously injected lead
at 1 day, 4% at 1 month, and less than 1%
at 3 years after injection. As with the liver
and kidneys, the model was designed to
yield reasonable consistency with the data
on chronically exposed humans, and the
injection data on baboons and beagles were
assumed to provide lower-bound estimates
for humans.
Excretion: Model Structure and
Transfer Rates
Excretion oflead is divided into four path-
ways: urinary excretion, fecal excretion,
sweat, and all other excretion pathways
combined (mainly hair, nails, and desqua-
mated skin). It is assumed that a portion of
lead entering the urinary bladder passes
directly from diffusible plasma to the uri-
nary bladder contents and the rest is
released to the bladder contents after tem-
porary retention in the renal tubules (com-
partment UP). Lead in feces is assumed to
originate from two sources: biliary secre-
tion from the liver contents (liver 1) into
the contents of the small intestine and
secretion from all other sources (assumed
to be diffusible plasma in this model) into
the contents of the small intestine. It is
assumed that the absorption fraction for
lead entering the small intestine in liver
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Figure 10. Model predictions (curves) and obser-
vations (symbols) of the rate of urinary excretion
of radiolead at early times after administration to
adult human subjects. Sources of data are indi-
cated.
bile or other secretions is the same as that
for ingested lead. Lead is assumed to be
transferred directly from diffusible plasma
to sweat. Losses in hair, nails, and desqua-
mated skin are represented as a transfer
from soft tissue compartment STI to exc-
reta.
There have been several studies of the
rate of urinary and fecal excretion of lead
after administration ofradiolead to human
subjects. It appears from the urinary excre-
tion curve for intravenously injected lead
that a few percent of administered lead
moves to the urinary bladder contents with
little or no delay in the kidneys (Fig. 10).
Urinary excretion curves for inhaled or
ingested lead reflect briefdelays in absorp-
tion to blood, superimposed on the excre-
tion curve for injected lead (Fig. 10). For
comparison of model predictions with
observed urinary excretion rates in hu-
mans, it is assumed that the urinary blad-
der is emptied completely with each void-
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Figure 11. Model predictions (curves) and obser-
vations ofthe rates of urinary and fecal excretion
of radiolead at early times after administration to
adult human subjects. Urinary excretion data
point for day 1 after injection is subject-weighted
mean of central values determined in Cham-
berlain et al. (27) (6 subjects, mean 3.7%), Booker
et al. (31) (2 subjects, mean 5%), Campbell et al.
(33) (2 subjects, mean 7.6%), Hursh et al. (41) (2
subjects, mean 4.2%), and Hursh and Mercer (44)
(4 subjects, mean 4.6%). Urinary excretion data
point for day 1 after inhalation is subject-weight-
ed mean of central values determined in (27) (12
subjects, mean 2.7%), (31) 2 subjects, mean 4.1%),
Hursh et al. (42) (10 subjects, mean 2.9%), and (44)
(4 subjects, mean 2.2%). Fecal excretion data
point for day 1 following inhalation is subject-
weighted mean of central values determined in
(27) (12 subjects, mean 0.7%) and (42) (median
1.7% determined from scattered data on 10 sub-
jects). All other data points are from (27) and are
meansfor7 orfewer subjects.
ing. For most purposes one can remove the
urinary bladder compartment from the
model or assume that removal from the
urinary bladder contents to urine follows
first-order kinetics; a removal half-time of
0.1 day seems reasonable, based on ICRP
data (54).
Typically, 2-5% of systemic lead is
excreted in urine during the first 24 hr
after administration (Fig. 11) (31,41,
42,44). There is little loss in feces during
the first day, but the fecal-to-urinary excre-
tion ratio is about 0.5 during days 2-14
after injection (Fig. 11) (27,28,32). The
fecal-to-urinary excretion ratio is slightly
higher (roughly 0.7-0.8) in the first 2
weeks after inhalation due to ciliary clear-
ance and swallowing of a small portion of
the lead deposited in the lungs (Fig. 11;
also see appendix). Urinary plus fecal losses
during the first 20 days account for about
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Figure 12. Model predictions (curve) and observa-
tions (circles) of the early urinary clearance of
intravenously injected radiolead expressed in
terms of the amount in blood plasma. Data points
are for one adult human subject(27).
30% of the administered amount in hu-
mans (28), compared with about 50% in
beagles and perhaps 40-50% in baboons
(18,49,82). The present model predicts that
about 27% of administered lead would be
lost in urine and feces during the first 20
days afterinjection into the adult human.
In an adult male subject acutely exposed
to210Pb43 years earlier, dailyurinary excre-
tion was estimated to represent about
0.0035% of the current body burden as
determined by in vivo measurements (107-).
The present model predicts that daily uri-
nary excretion at 43 years after acute intake
of lead would be 0.0049% of the current
body burden.
Some authors have expressed urinary
clearance oflead in terms ofthe amount of
lead in blood plasma or serum (Fig. 12)
(27,36), but it is more common to relate
this quantity to lead in the total blood vol-
ume. In humans exposed only to environ-
mental lead, urinary clearance oflead is typ-
ically 0.02 (range, 0.015-0.03) blood vol-
umes per day (9,18,57,128-131), which is
the valueproducedby the present model for
blood lead concentrations less than about
25 pgdl. As indicated in Figure 13 and dis-
cussed later in more detail, the daily urinary
clearance maysubstantially exceed this value
at high levels of BPb. The nonlinear rela-
tionship between lead in urine and lead in
blood appears to be similar to that between
plasma lead and BPb, insofar as compar-
isons arepossible. In this model, the nonlin-
ear relationship between urinary lead and
BPb is assumed to result from the increase
in diffusibleplasma lead as a fraction ofBPb
and not from nonlinear kinetics in the
kidneys.
Human data on urinary clearance of
lead are reproduced reasonably well by
assigning 1.5% of lead leaving diffusible
plasma to the urinary bladder contents, in
addition to the amountentering the bladder
contents after retention in the urina-ry path.
Recall that the latter accounts for 2% of
lead leaving diffusible plasma and is as-
sumed to be removed from the urinary path
to the bladdercontents with ahalf-time of5
days. The transfer rate from diffusible plas-
ma to the urinary bladder contents is 0.015
x (2000/day) = 30/day.
Human data on fecal excretion and on
the urinary-to-fecal excretion ratio for lead
are reproduced reasonably well by assigning
0.6% oflead leavingdiffusible plasma to the
contents of the small intestine. This is in
addition to the amount assumed to enter
the small intestine contents via biliary secre-
tion, which accounts forabout three-fourths
of total fecal excretion in this model. The
transfer rate from diffusible plasma to the
contents of the small intestine is 0.006 x
(2000/day) = 12/day.
The difficulties in measuring the loss of
lead in sweat are well recognized. Results of
some studies indicate that loss of lead in
sweat can approach or even exceed that in
urine under some conditions (135-139),
while other data suggest that sweat is not a
significant excretion pathway for lead
(27,140). The rate of transfer from plasma
to sweat used in the present model is acom-
promise value and is consistent with find-
ings of Rabinowitz and co-workers (9) for
human subjects ingesting a lead isotope
traceroveraperiodofmonths. Itis assumed
that 0.35% oflead leaving diffusible plasma
is removed from the body in sweat. That is,
the transfer rate from diffusible plasma to
sweat is 0.0035 x (2000/day) = 7/day. The
model predicts that total losses oflead in
sweat in the adult are about 10% as great as
losses in urineduringchronicexposure.
It is difficult to determine typical losses
oflead by other excretion pathways. Hair is
a well-known site ofconcentration ofinter-
nally deposited lead, but there is also conta-
mination ofhair from external sources (82.
As described earlier in the discussion ofthe
other soft tissues, it is assumed that 40% of
outflow from STI is in hair, nails, and
desquamated skin, which yields a transfer
rate from STI to excreta of 0.00277/day.
Fractional transfer from ST1 to excreta was
based primarily on measurements ofexcreta
from human subjects who ingested a lead
isotope tracer over a period ofmonths (9,
but data from less controlled studies oflead
in hair or nails were also considered
(141-144). With regard to minor excretion
pathways, the model is intended only to
approximate cumulative loss over an ex-
tended period. A precise treatment of the
time-dependent loss of lead in hair, for
example, from the time of acute intake
would require a considerably more complex
excretion model (16).
Modifications Needed toAddsres
Nonlinear Kinetics ofLead
The concentration oflead in blood is not
linearly related ta the concentration in
plasma or other fluids and tissues of the
body, at least when the blood lead concen-
tration substantially exceeds 25 pg/dl. This
nonlinear behavior oflead is not complete-
ly understood but may result in large part
from a reduced rate of flow from plasma
into RBCs as certain lead-binding compo-
nents of these cells become saturated
(17,18,20,39). It has been suggested, for
example, that the cell membrane may have
a limited capacity forlead (17,145). At low
levels ofexposure, lead in RBCs is associat-
ed primarily with hemoglobin (146). The
Hb A2 component of hemoglobin, which
represents only about 2% of the total
hemoglobin in human RBCs, may contain
one-halfto two-thirds ofthe lead in RBCs
at relatively low blood lead concentrations
(39,146). There appears to be saturation of
lead binding to Hb A2 at low to moderate
lead concentrations and an increase in the
portion of lead found in the main hemo-
globin component, Hb A, which may also
be saturable at moderate lead concentra-
tions (39). There is also evidence that an
elevated blood lead concentration induces
the formation of low-molecular-weight
lead-binding proteins within the RBCs
(39). The degree ofsynthesis of this pro-
tective lead-binding protein may depend
on the level and duration ofexposure, and
some persons may have diminished capaci-
tyforsynthesizing this protein (39).
Another potentially important lead-
binding component of RBCs that may
provide rapidly diminishing binding sites
at moderate blood lead concentrations js
the metalloenzyme 8-aminolevulinate
dehydratase (ALAD). Apparently, lead ions
can replace enzyme-activating zinc ions at
a small number of sites on ALAD, result-
ing in inactivation ofALAD and elevation
of 5-aminolevulinic acid (ALA) in blood
and urine (147). Urinary ALA increases
nonlinearly, perhaps exponentially, with
increases in the blood lead concentration,
at least at concentrations exceeding 30-40
/dl and possibly much lower (132,148).
Recent findings ofWetmur and co-work-
ers (147) indicate that the blood lead con-
centration is higher as an average in indi-
viduals with the ALAD 1-2 or 2-2 isozyme
phenotypes than in individuals with the
more common ALAD 1-1 isozyme pheno-
type.
In the present model it is assumed that
the observed nonlinear relations between
lead in blood and plasma, urine, or other
fluids and tissues result from a decrease in
the transfer rate from diffusible plasma to
RBCs as the concentration oflead in RBCs
increases. The available data do not clearly
reveal a threshold concentration oflead in
RBCs or blood at which a reduced rate of
flow into RBCs should be introduced, or
even if such a threshold exists. It is as-
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sumed here that such a threshold does exist
because a linear model appears to repro-
duce the data as well as a nonlinear model
at commonly encountered levels of lead,
and some software packages for solving
compartmental models do not allow the
use ofnonlinear kinetics.
Because ofthe uncertainty regarding the
magnitude (and existence) ofthe nonlinear
threshold and saturation levels in RBCs and
the potential variation in these quantities
from one exposure scenario to another,
these are induded as user-selected parameter
values of the model, although baseline val-
ues are given. It is assumed that the deposi-
tion fraction in RBCs remains at 0.24 until
the lead concentration, Y, in RBCs exceeds
a nonlinear threshold level, T, expressed in
/dl RBC. If Y> T, the deposition frac-
tion, D, in RBCs is given bytheequation
1.5 D= 0.24 x [1.0 - (Y-T)I(S-T)] ,
where Sis an assumed saturation concentra-
tion oflead in RBCs. This is an empirically
derived expression that can be used to
approximate observed relations between
lead in blood and that in urine or plasma
(Figs. 13 and 14, respectively). When Y> T,
the other deposition fractions in the model
are increased in proportion to their baseline
values to accommodate the decrease in the
deposition fraction for RBCs. That is, the
deposition fractions for compartments other
than RBCs are increased by the factor (1-
D)/(1-0.24) = 1.316(1-D). The total trans-
fer rate from diffusible plasma to all destina-
tions is assumed to remain at 2000/day
underall conditions.
Chamberlain (1k) suggested that non-
linear kinetics of lead is evident above a
blood lead concentration ofabout 25 /dl,
but other researchers have suggested that
virtuallylinearkinetics are obeyed up to lev-
els of 35-40 pg/dl blood. As a baseline
value, thenonlinear threshold concentration
Tissetat 60 g/dl RBC,which corresponds
to a blood lead concentration ofabout 25
/dl.
Selection ofa saturation concentration,
S, is complicated by its apparent depen-
dence on the level and duration ofexposure
and potential variation from one person to
another. As a baseline value, Sis set at 350
pg/dl RBC, based on consideration of the
level ofBPb atwhich the ratios urinarylead:
BPb and plasma lead: BPb begin to increase
rapidly in persons exposed for a long period
to high levels oflead (Figs. 13 and 14). A
much lower value for S, perhaps on the
order of 140 /dl RBC, may be better for
consideration of a high, acute intake by a
person with a history oflow intakes (Fig.
13).
Results of controlled studies in which
the blood lead level of human volunteers
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Figure 13. Model predictions (solid curves) and
observations (dashed curves) ofthe urinary clear-
ance of lead expressed in terms of the amount in
blood. Shaded area indicates typical values for
subjects chronically exposed to low levels of lead
(18,51, 115,130). Curves 1 and 2 summarize data
for two volunteers receiving a short heavy, con-
trolled exposure to lead (132). Curve 3 summarizes
data ofCooper at al. (133 on about300 employees
of a lead smelter and refinery. Curve 4 summa-
rizes data ofSkerfving et al. (134) for a lead work-
er. Model predictions assume an exposure-
dependent saturation concentration in RBCs. For
an acute intake by a person with a history of low
intakes, the assumed RBC saturation level is 140
pg/dl RBC. For chronic intake of high levels of
lead, the assumed RBC saturation level is 350
pg/dl RBC.
was increased to 35-40 jig/dl or higher
over aperiod ofweeks or months (149-151)
seem more nearly consistent with the
chronic exposure model than the acute
exposure model indicated above. That is,
values of Sclose to 350 pg/dl RBC appear
to produce better agreement between
model predictions and those results than
do values near 140 jig/dl 'RBC. However,
the data from those studies are too scat-
tered and the uncertainties in the amount
of lead absorbed to blood in each case are
too large to draw strong conclusions in this
regard. The results of Kehoe (149) are
inconsistent with the strictly linear model
described in previous sections, while the
results ofGriffin et al. (150) and Cools et
al. (151) can be explained about as well
with the linear model as the nonlinear
model with Snear 350jig/dl RBC.
Modffcation ofParameterValues
forApplication to Children
ICRP Publication 56, Part 2 (22) intro-
duces a generic approach for development
ofage-specific parameter values for calci-
umlike elements [also see Leggett (91)].
On the basis of data from a large number
of studies on the fate of radioisotopes of
calcium and related elements in laboratory
animals and humans, it is postulated that
differences with age in the biokinetics of
these elements arise mainly from three
related events: 1) increased fractional trans-
fer from plasma to bone in children in
association with the relatively greater rate
ofaddition ofcalcium to bone in children
IL 2e-
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Figure 14. Model predictions and observations of
the nonlinear relation between blood lead and
plasma lead. The dashed curves representing
observations are fits to data of Manton and Cook
(31) or deSilva (M3.
than adults; 2) decreased fractional transfer
from plasma to soft tissues and excreta in
children due to relatively greater competi-
tion from immature bone; and 3) an ele-
vated rate of transfer from nonexchange-
able bone to diff-usible plasma in children
due to an elevated rate of bone turnover.
Except where there is evidence to the con-
trary, removal half-times from soft tissues,
bone surfaces, and exchangeable bone vol-
ume are assumed to be independent ofage.
For some calciumlike elements, including
lead, available data are consistent with the
assumption that the size of the exchange-
able pool of bone is greater in children
than in adults. Within the context of the
present model structure or the slightly sim-
pler structure used in ICRP Publication 56
(22), this means that an atom entering
bone has a smaller probability ofreaching
nonexchangeable bone in children than in
adults.
This generic approach appears to be
consistent with information on the age-
specific kinetics of radiolead in laboratory
animals (13,14,50,120,127,152-158). For
example, Mallon and co-workers (13,14)
concluded from data on baboons exposed
acutely or chronically to20Pb that skeletal
uptake ofabsorbed lead was much greater
in rapidly growing animals than in more
X 1=~~~~1
mature animals. In a 20Pb-ingestion
experiment with 10-days-old, 150-daym-old,
and adult Macaca irus monkeys, skeletal
tissues of the two younger groups con-
tained a substantially larger portion of sys-
temic 210BPb than did those of adult mon-
keys at 4 days after oral dosing (50). In a
similar experiment with rhesus monkeys,
infants (ages 5-7 months) excretedla sub-
stantially smaller fraction of the absorbed
amount than did adults during the first 23
days after administration (156).
Anotherperspective on differences with
age in the biological behavior of lead is
provided by autopsy data on human sub-
jects exposed to environmental lead. These
data can be used to derive reference organ
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distributions of lead for different age
groups, and these reference distributions
can serve as constraints on model parame-
ters. Several different adult populations
have been studied, but reference distribu-
tions for children must be based to a large
extent on data from a single study involv-
ing a large number of subjects from an
industrialized region ofEngland, including
18 subjects of age 1-10 years and 6 sub-
jects of age 11-16 years (114). Thus,
because of the substantial uncertainties in
the accuracy and universality of the refer-
ence distributions for children, they should
be treated only as first estimates rather
than definitive data.
The derived reference organ distribu-
tions are indicated in Table 3, where they
are represented as ranges ofvalues rather
than point estimates to emphasize the
uncertainties involved. The method of
development of these uncertainty ranges
will be described in detail in another paper.
Briefly, baseline contents (expressed as frac-
tions of the total-body content) of lead in
different tissues of a middle-aged adult
male are based on medians oflead concen-
trations determined in the relatively de-
tailed investigations by Gross and co-work-
ers (112), Barry (113,114), and Tipton and
co-workers (159-161). To reduce results
from these three different studies to a com-
mon basis, reported concentrations from
each study were normalized to a liver con-
centration of 1 ppm wet weight. Con-
centrations reported by Barry (114) were
used as baseline values for the younger ages.
Data from these studies were compared
with findings from a variety ofless compre-
hensive post-mortem studies in an effort to
determine how well these baseline organ
contents might represent an arbitrary study
group. The ranges of values indicated in
Table 3 were derived from a kind ofpara-
meter uncertainty analysis in which the
major parameters used to derive the refer-
ence distributions were varied simultane-
ously within reasonable ranges of uncer-
tainty. It was considered, for example, that
1) the relative concentrations oflead in dif-
ferent organs vary from one study group to
another; 2) there may be problems associat-
ed with analytical techniques and contami-
nation of samples, particularly for tissues
with low concentrations of lead; 3) the
sampling sites may not be representative of
the whole organ or tissue; and 4) the mass
oftissue represented by a reported concen-
tration is often not well known (e.g., tra-
becular bone usually contains more soft tis-
sue than bone tissue). The derived ranges of
values (Table 3) cannot be interpreted as
precise probability statements, but it is like-
ly that the true relative organ contents
under conditions of chronic exposure
would fall within the indicated ranges.
Table 3. The distribution of lead in humans chronically exposed to a low level of lead throughout life, as
calculated from postmortem data and as predicted bythis modelab
Age,yearsa
Tissue 1-5 6-9 11-16 20-30 40-50
Bone
Postmortem data 0.45-0.80 0.50-0.80 0.55-0.85 0.75-0.90 0.85-0.95
Model prediction 0.66 0.69 0.79 0.88 0.90
Blood
Postmortem data 0.03-0.08 0.03-0.08 0.03-0.08 0.015-0.035 0.008-0.02
Model prediction 0.045 0.055 0.04 0.025 0.02
Liver
Postmortem data 0.05-0.10 0.05-0.10 0.04-0.10 0.03-0.07 0.015-0.035
Model prediction 0.08 0.065 0.065 0.04 0.03
Kidneys
Postmortem data 0.007-0.015 0.006-0.015 0.005-0.010 0.003-0.007 0.002-0.004
Model prediction 0.012 0.009 0.006 0.004 0.003
Brain
Postmortem data 0.009-0.025 0.007-0.015 0.004-0.009 0.002-0.004 0.0008-0.002
Model prediction 0.018 0.01 0.004 0.002 0.002
Other
Postmortem data 0.12-0.35 0.10-0.32 0.08-0.30 0.04-0.15 0.02-0.08
Model prediction 0.185 0.17 0.09 0.05 0.045
'Values are expressed asfractions oftotal body lead. bModel predictions are for ages 3,7, 13, 25, and 45years, respectively.
In the development of the present
model for children, the reference distribu-
tions were first used to test provisional para-
metervalues forchildren thatwere based on
a set ofgeneric assumptions concerning dif-
ferences with age in the behavior of calci-
umlike elements. Some adjustments of the
provisional parameter values were then
made to obtain acceptable agreement
between model predictions and the refer-
ence distributions foryoungchildren. Itwas
found that thepredicted age-specificdistrib-
utions varied little with the exposure sce-
nario, provided the rate ofuptake oflead to
blood was not radically altered over aperiod
of a few months. Thus, predictions were
based on a simple scenario of constant
uptake (20 pg/day) to blood throughout
life. In this model, the lead content of the
various compartments at birth are derived
from the assumed content in the mother's
blood. The concentration oflead in blood
at birth is assumed to be 0.85 times that of
the mother's blood, based on a variety of
studies (162). The relative contents ofbone,
blood, liver, kidneys, brain, and other soft
tissues at birth are assumed to be 0.32, 0.07,
0.055, 0.01, 0.045, and 0.5, respectively,
based mainly on data of Barry (114); for
multiple-compartment organs, the contents
at birth are assumed to reside in thelongest-
term compartment. For the exposure sce-
nario considered here, the concentration of
lead in the mother's blood is assumed to be
thatcalculated for a25-year-old personwith
chronic uptakeof20 pgPb/day.
The provisional age-specific parameter
values were based on the following generic
assumptions (1-5 below), which were
applied earlier to the alkaline earth ele-
ments (22,91).
Generic assumption 1. Fractional depo-
sition on bone surfaces is proportional to
the rate of addition of calcium due to
modeling and remodeling of the given
bone type (trabecular or cortical). The esti-
mated average calcium addition rate for
adults (0.25 g/day) and the deposition
fraction for bone in the typical adult serve
as the points of reference. The model for
the rate ofaddition ofcalcium to the skele-
ton is described elsewhere (91).
Genericassumption 2. The total transfer
rate from nonexchangeable bone volume is
equal to the bone turnover rate and thus
varies with age. The model for the rate of
turnover ofcortical and trabecular bone in
children is described elsewhere (21,97-).
Generic assumption 3. At all ages, corti-
cal bone represents 80% and trabecular
bone the remaining 20% of total bone
(97). This assumption is based on mea-
surements on the adult human skeleton
(54). The relative amounts ofcortical and
trabecular bone in children cannot be esti-
mated with much confidence, particularly
for the first few years of life. As it turns
out, model predictions are fairly insensitive
to the division between cortical and trabec-
ular bone in children because, as indicated
by data for the alkaline earth elements and
depicted in this model, there is little dis-
tinction between trabecular and cortical
bone in children with regard to the kinetics
ofcalciumlike elements. The model depicts
trabecular and cortical bone as growing at
the same rate and as having fairly similar
remodeling rates during childhood. Bone
remodeling rates are assumed to be identi-
cal in the two bone types during infancy
and to diverge gradually during childhood
and adolescence. As a consequence of
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becular to cortical deposition ratio ofa cal-
ciumlike element increases from 0.25 in
infants (since there is assumed to be one-
fourth as much trabecular as cortical bone
and the growth and turnover rates are
assumed to be the same for the two bone
types in infants) to 0.34 at age 10 years, for
example, and to 1.25 in mature adults.
Bone originally laid down as trabecular
bone but converted to compact bone dur-
ing growth is assumed to have been corti-
cal bone throughout its existence.
Generic assumption 4. In children,
deposition fractions for soft tissues and
excreta are reduced uniformly because of
the higher deposition in bone. This as-
sumption is intended to apply to the distri-
bution that would be seen after the early,
rapid exchange between diffusible plasma
and extravascular fluids is largely complete.
Thus, it is implemented by ignoring any
potential short-term effects on the extra-
vascular fluid compartffient, EVF. Com-
partment EVF is assumed to receive 50%
of instantaneous outflow from diffusible
plasma at all ages, and reduced transfer
from diffusible plasma to soft tissues and
excreta ofchildren is described in terms of
the remaining 50% of outflow from dif-
fusible plasma. As an example, the deposi-
tion fraction assigned to all bone surfaces
combined is 0.08 for mature adults and, as
derived from generic assumption 1, 0.24
for infants. For the infant, the deposition
fractions for soft tissue compartments or
excretion pathways are determined as (0.5-
0.24)/(0.5-0.08) = 0.619 times the corre-
sponding deposition fractions for adults.
This approach is reasonably consistent
with the limited age-specific data on lead
in nonhuman primates (13,50,156).
Generic assumption 5. Removal half-
times from soft tissues, bone surfaces, and
exchangeable bone volume are indepen-
dent of age. As described later, it seems
appropriate to relax this assumption forthe
case oflead in the liver and kidneys. Also,
limited information suggests that the rate
ofremoval ofalkaline earth elements from
exchangeable bone may be greater in chil-
dren than in adults, but the present as-
sumption seems reasonable until age-spe-
cific rates can be better supported and
quantified. Note that this assumption
applies to total outflow from bone surfaces
and exchangeable bone volume and does
not address the destination ofoutflow.
A sixth assumption regarding the rela-
tive exchangeability of bone deposits in
children and adults is applied in ICRP
Publication 56 (22) on an element-by-ele-
ment basis. There is evidence that ex-
changeability of strontium decreases with
increasing bone age, but itprobably should
not be assumed that this phenomenon
applies uniformly to all alkaline earth ele-
ments because it appears to be less pro-
nounced for calcium than for strontium
(91). An assumption ofelevated exchange-
ability ofbone deposits in children leads to
improved agreement between model pre-
dictions and autopsy data on persons
exposed to environmental 90Sr and thus is
applied by ICRP (22) to strontium. This
assumption could not be tested for barium
and radium and is not applied in the ICRP
document to these elements. The assump-
tion is implemented for strontium by
assigning greater fractional transfer from
bone surfaces to diffusible plasma in chil-
dren than in adults. It could be imple-
mented in other ways, such as by assigning
a greater fractional return from exchange-
able bone volume to bone surfaces in chil-
dren, but the available data on strontium
seem consistent with the requirement that
the elevated exchange ofbone strontium in
children be manifested fairly rapidly.
There is no direct evidence ofdecreas-
ing exchangeability oflead with increasing
bone age. The situation for lead is other-
wise similar to that for strontium, however,
in that an assumption of elevated ex-
changeability of bone deposits in children
helps reduce discrepancies between predic-
tions of a provisional model based on
assumptions 1-5 and autopsy data for
environmentally exposed children. There-
fore, the following assumption is made for
lead.
Assumption 6 There is greater fraction-
al transfer from bone surfaces to diffusible
plasma in children than in adults. By anal-
ogywith strontium, it is assumed that frac-
tional return from bone surfaces to plasma
is 1.25 times higher at ages 0-15 years
than in adults. For lead, this means that
1.25 x 50% = 62.5%, rounded to 65%, of
the amount leaving bone surfaces goes to
diffusible plasma and 35% goes to ex-
changeable bonevolume.
As the total transfer rate from bone sur-
faces is assumed to be 1/day, as in adults
(see generic assumption 5), the transfer
rate from (trabecular or cortical) bone sur-
faces to diffusible plasma in children is
0.65 x (1/day) = 0.65/day, and the transfer
rate from bone surfaces to exchangeable
bonevolume is 0.35/day.
The addition ofassumption 6 improves
agreement between model predictions and
reference distributions for children, partic-
ularly for bone, but noticeable discrepan-
cies remain for some compartments at
some ages. For example, the liver and kid-
neys do not appear to be important reposi-
tories oflead in young children, but ifthe
parameter values for adults are applied to
these organs during childhood, the model
predicts substantial buildup in the first few
years oflife, due mainly to accumulation
in the long-term compartments assumed to
exist in each organ. Thus, it seems reason-
able to reduce the removal half-time for
these compartments inyoung children.
Assumption 7. The removal half-time
from the long-term compartments ofliver
and kidneys to diffusible plasma is 100
days for ages 0-5 years. The removal half-
time for ages 10 years and 15 years is the
same as for adults (1 year). Recall that
transfer rates for ages intermediate to those
indicated in Table 1 are calculated by lin-
ear interpolation (with age) ofthe transfer
rates given in the table.
Although some discrepancies remain
between model predictions and reference
distributions after application of the seven
assumptions indicated above, further com-
plications ofthe model based on these ref-
erence distributions for children do not
appear to bejustified for purposes ofradia-
tion protection. For example, assumptions
1-7 yield higher fractional content in
blood and lower fractional content in other
soft tissues than indicated by the reference
distributions for children. Estimates of
dose from internally deposited radioiso-
topes oflead are not altered much, howev-
er, byforcing the model to fit the reference
values for other soft tissues and blood; this
is because the predicted and reference dis-
tributions agree reasonably well with
regard to the sum ofthe fractional contents
ofother soft tissues and blood, and, in cal-
culation of radiation doses, radiological
decays in blood are assigned primarily to
the organs and tissues making up othersoft
tissues.
While the ability to predict the level of
lead in blood in chronically exposed chil-
dren may not be critical for radiation pro-
tection purposes, the BPb level is the pri-
mary index used in the development of
exposure guidance for stable lead. Thus,
for consideration of lead as a chemical
toxin, it seems worthwhile to introduce
greater detail into the model to reproduce
more closely the fractional contents in
blood indicated by the reference distribu-
tions for children.
Data on nonhuman primates (13,50)
suggest that there maybe smaller uptake of
lead by RBCs and/or faster removal from
RBCs in young animals than in mature
animals. Also, model predictions for chil-
dren can be brought into line better with
reference fractional contents of blood in
children and data on intakes and blood
levels oflead in infants (163) by assigning
to the younger age groups either a smaller
deposition fraction to RBCs or a shorter
removal half-time to RBCs. There is little
basis for choosing between these two
approaches, except that within the present
scheme it is simpler to assign a shorter
removal half-time.
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from RBCs is shorterinyoungchildren than
in adults. The following removal half-times
from RBCs to diffusible plasma are chosen
for reasonable consistency with the reference
distributions: ages 0-1 years, 1.5 days; ages 5
years, 2.5 days; ages2 I0 years, 5 days.
The derived reference distributions indi-
cate that the fractional content ofother soft
tissues is considerably greater in young chil-
dren than in adults. The relativelyhigh con-
tent estimated for this group of tissues at
young ages can be traced to the high por-
tion ofthe bodyweight represented by skin
and fat and the high reported concentra-
tions oflead in fat in young children com-
pared with adults. The high reported con-
centration oflead in fat in children could be
partly an artifact ofthe autopsy data, given
the considerable technical problems in
obtaining representative samples offat and
accurately determining the low concentra-
tions of lead in those samples on a fresh-
weight basis. In this model, the indicated
higher content ofother soft tissues is taken
at face value and is explained by a higher
deposition fraction for compartment STI
because ofits association with skin and fat.
The elevated uptake by STI is balanced by
reducing inflow to the rapid-turnover soft-
tissue compartment, STO, one of whose
purposes in this model is to receive leftover
lead after the other compartments have
been addressed.
Assumption 9. The deposition fraction
in the intermediate-turnover compartment,
ST1, is two times higher at ages 0-15 years
than in adults. The higher deposition in
ST1 at these ages is balanced by lower
deposition in STO.
The brain is not considered as a sepa-
rate organ in ICRP's model for lead (22
but is part ofother soft tissues. Although
autopsy results indicate that the concentra-
tion oflead in brain may be lower in chil-
dren than in adults, the brain is estimated
to contain a much higher portion oftotal
body lead in infants and young children
than adults because of its relatively greater
mass (as a percentage oftotal body mass) at
the younger ages. This is supported by
comparative data on mature and immature
baboons administered radiolead (18). In
this model, the relatively higher content of
brain atyoung ages is explained by a higher
deposition fraction forbrain.
Assumption 10. The deposition fraction
in brain is three times higher at ages 0-1
years than in adults, due to the relatively
greater mass of brain as a percentage of
total body weight. The deposition fraction
for brain is assumed to dedine linearlywith
age to 5 years, when the adult value is
reached. The higher deposition in brain at
ages 0-5 years is balanced by assigning a
slightly lower deposition fraction to STO.
Summary and Conclusions
Several different types ofinformation con-
tribute to ourunderstandingofthe behavior
oflead in the human body. These indude
results oflead tracerstudies on healthyadult
human volunteers; measurements oflead in
autopsy samples from environmentally
exposed humans ofall ages; results oflead
balance studies on adult humans; bioassay
data and autopsy measurements on persons
occupationally exposed to lead; data from
controlled studies ofthe behavior of radi-
olead in laboratory animals at different
stages oflife; and data on the age-specific
kinetics of the chemically and, in many
respects, physiologically similar alkaline
earth elements in humans and laboratory
animals.
In this paper an attempt has been made
to synthesize all ofthe different sources of
information into an age-specific biokinetic
model for lead. The data were organized
within a compartmental model structure
originallydeveloped for consideration ofthe
age-specific biokinetics ofadass ofcalcium-
like radionuclides. The model structure rep-
resents a compromise between biological
realism and practical considerations regard-
ing the quantity and quality ofinformation
available to determine parameter values.
Transport oflead between compartments is
assumed to follow linear, first-order kinetics
provided the concentration in red blood
cells remains below a nonlinear threshold
level, but a nonlinear relation between plas-
ma lead and red blood cell lead is modeled
forconcentrations abovethatlevel.
The model appears to be a fairly accu-
rate predictor for adult humans exposed to
relatively low levels oflead. It is proposed
only as a reasonable starting point for mod-
eling the biokinetics oflead in children or
the kinetics oflead at high levels ofexpo-
sure. The modular design ofthis model is
intended to allow researchers to modify spe-
cific parametervalues or model components
to address special problems in lead toxicolo-
gy or to incorporate new information. For
example, one could substitute a detailed
model of the brain for the present single-
compartment brain without adjusting other
components ofthemodel.
Appendix
Respitory and Gastrointesinal
Tract Models forLead
Respiratoy TractModel
Fractional deposition ofinhaled lead in the
lungs varies with the size of the inhaled
material, the breathing rate, and other fac-
tors. A value ofabout 0.35-0.40 may be a
reasonable central estimate, but deposition
fractions as low as 0.15 or as high as 0.75
may not be uncommon (18,27,31,42,44,
45,128,150,164).
Experimental data for human subjects
indicate that 85% or more of deposited
lead is deared from the lungs with an effec-
tive biological half-time on the order of
0.2-0.6 day, if clearance is expressed in
terms of one or two components (27,31,
32,42,44,45,165,166). Similarly, a biologi-
cal half-time of about 0.5 day has been
found for dogs (167). A more detailed
description was given by Chamberlain and
co-workers (27, who found that for de-
posited 203PbO, 203Pb(NO3)2, or "dean"
Pb-labeled exhaust aerosols, approxi-
mately 22% was cleared with Ti12 = 0.8
hr, 34% with Ti12 = 2.5 hr, 33% with Ti12
= 9 hr, and 12%with T,12 = 44 hr. Forcar-
bonaceous 203Pb-labeled exhaust aerosols,
approximately 29% was clearedwith Tj,2 =
0.5 hr, 50% with Ti12 = 4.5 hr, 6% with
Ti12 = 24hr, and 15%with Ti,2 = 220 hr.
Fractional uptake of deposited lead to
blood depends on the form and particle
size of inhaled lead. For submicrometer
aerosols there appears to be little ciliary
clearance of deposited lead. For example,
results ofHursh et al. (42) and Wells et al.
(32) indicate that about 95% ofdeposited
lead was absorbed directly to blood. When
inhaled as a vapor, as much as 35-40% of
deposited lead might be removed to the
stomach, and the rest is absorbed directly
to blood (31).
Based on the above information, the
following lung model was adopted for
comparison of model predictions with
observations on the behavior of inhaled
lead. The deposition fraction for unknown
forms oflead is set at 0.37. (Alung deposi-
tion fraction was not needed for present
purposes, because data from inhalation
studies were related to the deposited
amount rather than the inhaled amount.)
Ofthe deposited amount, 20% is assumed
to be deared with Tll = 1 hr, 35% with
T112 = 3 hr, 35% with Tj/2 = 9 hr, and
10% with T1/2 = 2 days, with 95% of
deared lead absorbed directly to blood and
5% moving to the stomach via ciliary
dearance. Greater ciliary dearance may be
expected in industrial exposures, where
aerosol particles are often larger (18), or
with lead inhaled as a vapor (31). It is
assumed that the behavior oflead deposit-
ed in thelungs is independent ofage.
Gastrointestinal TractModd
For persons > 18 years old, movement of
lead through the gastrointestinal tract is
assumed to follow the gastrointestinal tract
model ofthe ICRP (12). That is, material
is assumed to move in sequence through
four segments ofthe GI tract: stomach (S),
small intestine (SI), upper large intestine
(ULI), and lower large intestine (LLI).
Absorption from the gastrointestinal tract
is assumed to occur only in segment SI.
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Transfer from one segment to another is
assumed to follow first-order kinetics. In
adults, transfer rates out ofsegments S, SI,
ULI, and LLI are 24, 6, 1.85, and 1/day,
respectively. For children age 0-12 years,
the removal half-time from each segment is
assumed to be 0.6 times the adult value,
based on data ofCorazziari and co-workers
(168). Values for ages 12-18 years are
based on interpolation of the 12-year and
18-year values. Lead transferred from the
liver or from plasma into the contents of
the gastrointestinal tract is assigned to seg-
ment SI and is assumed to be reabsorbed
to plasma at the same rate as ingested lead.
Absorption of lead from the gastroin-
testinal tract has been studied extensively
and depends strongly on a variety of fac-
tors, including the level of calcium, phos-
phorus, zinc, iron, fat, protein, and vita-
min D present in the intestines; the body's
iron or zinc status; the amount of lead
administered; the physical and chemical
form administered; and the time offasting
(6,13,169-175). It is not surprising, then,
that a large range of gastrointestinal
absorption fractions (0.01-0.8) have been
reported. Most measurements on adult
humans have fallen in the range 0.03-0.2
for intake with solids (9,27,173,176-180),
0.08-0.30 for intake with liquid between
meals (27,181), and 0.3-0.7 for ingestion
with liquids after several hours of fasting
(9,27,173,177,179,180). Most balance
studies have indicated values of10% or less
(101,149,182-184), but reanalysis of bal-
ance data in view of current information
on endogenous fecal excretion oflead indi-
cates that an estimate of 0.15 or greater
might be more appropriate (27,128).
Balance studies suggest that infants and
children may absorb 40% or more of
ingested lead (185-188), but results of
these studies are highly variable and incon-
clusive. Data on monkeys (50,156) and
rats (152,157,189,190) generally indicate
substantially higher absorption of lead in
growing than in mature animals.
In ICRP Publication 56 (22), absorp-
tion fractions assigned to infants, ages
1-15 years, and adults are 0.6, 0.4, and
0.2, respectively. In this paper the same
pattern is assumed, but the values are
reduced by 25%, to 0.45 in infants (de-
fined here as 0-100 days of age), 0.3 at
ages 1-15 years, and 0.15 in adults (2 25
years). Linearly interpolated values are used
for ages between 100 days and 1 year or
between 15 years and 25 years. For exam-
ple, the value for age 20 years is (0.5 x
0.3)+(0.5 x 0.15) = 0.225.
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